Vyant Bio, Inc. announced that in accordance with the amended merger agreement, on March 30, 2021, the Board appointed the following officers of the company, effective at the Effective Time: Andrew D.C. LaFrence, CPA as Chief Financial Officer. Andrew D.C. LaFrence joined StemoniX as its Chief Financial Officer in August 2019 and, since March 2020, he has also served as its Chief Operating Officer. Mr. LaFrence has 36 years of accounting and finance experience, including executive management positions at public and private life sciences companies.